Sustained electrographic suppression of the spike-wave burden during the sleep window is the single best-documented driver of cognitive preservation in DEE-SWAS.

For Levi specifically, the 3-day IV methylprednisolone pulse produced near-total electrographic resolution within two weeks - a concrete, individually-demonstrated response. The broader DEE-SWAS/CSWS literature (Buzatu 2009, Kotagal 2017, van den Munckhof 2024 RESCUE-ESES RCT, 2025 DEE-SWAS strategies review) supports corticosteroids as a first-line option with roughly 45-70 percent response rates and with durability contingent on taper design. Evidence quality is moderate rather than strong because most DEE-SWAS steroid data come from observational cohorts with heterogeneous protocols, not multi-arm RCTs.

• →Repeat overnight EEG in 4-8 weeks with quantitative SWI.
• →Pre-specify thresholds that would trigger an additional steroid pulse, a slower taper, or a switch to steroid-sparing immunomodulation.
• →Track clinical markers reported by caregivers (eye contact, eloping, AAC use, playground engagement) alongside electrographic data.

Iron is a cofactor for dopamine synthesis, regulates sleep architecture, and has documented effects on seizure threshold. Iron deficiency is high-likelihood amplifier that is independently treatable with low downside.

Multiple pediatric studies and meta-analyses (2017 iron-deficiency-seizure-threshold model, 2024 febrile seizures meta-analysis) link iron deficiency to increased seizure susceptibility and to cognitive / sleep dysfunction. Iron repletion is low-risk and independently indicated for Levi's serial labs. Evidence is moderate rather than strong because randomized data specifically on seizure-outcome benefit of iron repletion in non-febrile DEE are limited.

• →Start oral iron (ferrous sulfate or sucrosomial iron) per pediatrics dosing.
• →Recheck iron studies in 2-3 months.
• →If oral iron is poorly tolerated or malabsorption is suspected, escalate to IV iron per hematology.

Levi's baseline cardiac rhythm and QTc are currently unknown. The two 2024 Stanford EKGs were both captured while Levi was not cooperative (the July tracing also carries documented baseline artifact) and should be treated as uninterpretable rather than as evidence of a persistent borderline QTc. A cooperative repeat EKG is needed before any AED, stimulant, tricyclic, SSRI, atypical antipsychotic, or other QT-prolonging agent is started.

Pre-prescription cardiology review and a cooperative baseline EKG are standard of care before starting a QT-prolonging pediatric regimen when a usable baseline tracing is not on file. Not a disease-modifying therapy, but well-supported as a safety policy. Prevents avoidable iatrogenic arrhythmia.

• →Add a standing "cardiology review before QT-prolonging drug" requirement to the care plan.
• →Schedule a cooperative repeat EKG (with pediatric-friendly positioning / desensitization if needed) before starting any candidate drug with QT liability.
• →2026-04-17 - the earlier framing of a "persistent borderline QTc (460 -> 452)" across the 2024 tracings is retired; treat baseline as unknown.

If the spike-wave burden returns or the Th1/Th17 serum signature persists off steroids, DEE-SWAS evidence base supports IVIG or repeated IV steroid pulses as second-line immune-directed therapy.

RESCUE-ESES RCT (van den Munckhof 2024) directly compares corticosteroids vs clobazam as first-line in ESES and supports continued use of steroid-based regimens. Saudi multicenter IVIG observational data (2023) and the European steroid-practice survey (2025) describe real-world use of IVIG and pulsed methylprednisolone with documented but heterogeneous response. Evidence is limited rather than moderate because pediatric DEE-SWAS data on IVIG and repeated pulses remain observational and non-randomized.

• →Discuss contingent plan with UCSF neurology team and Stanford epileptology.
• →Obtain repeat serum cytokine panel off steroids.
• →If CSF cytokines confirm CNS inflammation, this family moves up.

Both sulthiame and high-dose benzodiazepine protocols are part of the established DEE-SWAS toolkit and can be used alongside or instead of steroid-based immunomodulation.

Both sulthiame and high-dose benzodiazepine protocols have observational evidence supporting their use in ESES/CSWS/DEE-SWAS. Kotagal 2017 reviews dosing regimens and response rates. The RESCUE-ESES RCT compares steroids to clobazam as first-line and documents meaningful response in the clobazam arm. Sulthiame is used extensively in European centers. Evidence is moderate-strength for ESES-spectrum; extrapolation to Levi's current stable-on-steroids state is indirect.

• →Confirm availability / supply considerations (sulthiame US availability can be constrained).
• →Discuss risk-benefit with Stanford epileptology.

Ketogenic diet has documented efficacy in a subset of DEE-SWAS cases and is an option especially if drug-based approaches are insufficient or are complicated by QT concerns.

Ketogenic diet has observational evidence in drug-resistant pediatric epilepsy and subsets of ESES/CSWS/DEE-SWAS. The 2025 DEE-SWAS treatment strategies review and the Practical Neurology DEE-SWAS review both list ketogenic diet as a considered second- or third-line option. Evidence in DEE-SWAS specifically is limited and observational rather than randomized; response is heterogeneous and depends heavily on diet team experience.

• →Identify a ketogenic dietitian and pediatric neurology team at Stanford or UCSF if this becomes relevant.

mTOR inhibitors (sirolimus, everolimus) have established roles in TSC-associated epilepsy and in PTEN/PI3K-AKT-pathway-positive disease. Alpelisib (PI3K-alpha inhibitor) is FDA-approved for PIK3CA-related overgrowth spectrum (PROS) in patients >=2 years. Without pathway-positive genetic confirmation, the risk-benefit does not favor empiric use in a child with Levi's current picture. Two negative germline workups have made empiric use less defensible, not more.

Pathway-positive disease has substantial evidence (everolimus for TSC-associated epilepsy is FDA-approved based on the EXIST-3 trial). Beyond TSC, mTOR inhibitors have published rationale and pre-clinical support (Roy 2015 PIK3CA mouse models; 2021 mTORopathies precision-medicine review; Lasser 2024 PTEN mTORC1/mTORC2 biology) but limited prospective human data outside TSC. Evidence for empiric use without genetic confirmation is insufficient and the risk profile does not support it.

• →Germline workup is now complete (Stanford exome + GeneDx WGS + reanalysis all negative). The next gate is tissue-based mosaic-sensitive sequencing per diagnostic `mosaic-sensitive-tissue-sequencing`.
• →If a pathway-positive mosaic variant is identified, revisit with Stanford epileptology, medical genetics, and a PROS / mTOR-experienced center.
• →If negative, do not escalate to empiric mTOR inhibition.

The period immediately after spike-wave normalization is the window in which cognitive and language gains are most likely. Intensive speech / language / OT during this window is consistent with the DEE-SWAS recovery literature.

Early intensive developmental therapy during periods of electrographic suppression is consistent with general pediatric neurodevelopmental practice and with DEE-SWAS-specific recovery observations (Kotagal 2017, DEE-SWAS strategies review 2025). Evidence is moderate rather than strong because studies are observational; however, the intervention itself is low-risk and independently indicated.

Research registries and natural-history studies provide access to longitudinal cohort comparisons, genetic reanalysis, and advanced diagnostic options.

Registries are not a therapeutic intervention per se. Their "efficacy" is access to diagnostic reanalysis and trial opportunities over time. Value is indirect but well-established in rare-disease pediatric neurology.

Polyethylene glycol 3350 is an osmotic laxative that softens stool and eases evacuation without systemic absorption. Untreated chronic constipation in a child with sensory and behavioral restrictions is a disproportionate driver of behavioral disruption, sleep disruption, and treatment non-adherence.

Polyethylene glycol 3350 is the best-studied first-line pediatric laxative and is standard of care for functional constipation in children. Safety profile at maintenance dosing is well-characterized across pediatric populations.

• →Keep a running record of frequency and Bristol stool chart type so escalation / de-escalation decisions are grounded.
• →Pair with hydration and fiber where tolerable.
• →If ineffective at appropriate dose, reassess with pediatrics for alternatives.

TCAs, some SSRIs, stimulants, and some atypical antipsychotics can prolong QT. Levi's baseline QTc is currently unknown because the 2024 Stanford EKGs were captured while he was not cooperative and should not be treated as a usable baseline. The conservative default is therefore to avoid QT-prolonging psychopharm until a cooperative repeat EKG is obtained and a cardiologist has reviewed it.

Avoidance of QT-prolonging drugs until a cooperative baseline EKG is on file and has been reviewed by pediatric cardiology is standard of care. Safety guardrail, not a disease-modifying therapy.

A small mixed carbohydrate-protein snack 30-60 minutes before bed slows overnight glucose decline and blunts the early-morning counter-regulatory cortisol/ACTH/catecholamine surge in children with marginal glucose reserves. Maines 2021 establishes that PI3K-AKT-mTOR pathway defects can cause occult childhood hypoglycemia, including hypoglycemia presenting as nocturnal awakening. Even in the absence of confirmed hypoglycemia, a pre-bedtime snack is a cheap, reversible probe of whether the 1.5-year nocturnal arousal phenotype has a glycemic / counter-regulatory contribution.

Pre-bedtime snack is a standard pediatric-endocrinology recommendation for children with marginal overnight glucose reserves (e.g., glycogen storage disease, hyperinsulinism, GH deficiency, hypopituitarism) and is widely used as a first-pass probe even before formal critical-sample workup. Evidence for symptomatic improvement is largely observational. For Levi specifically, the test is low-risk and high-information regardless of mechanism - either it reduces awakenings (supports glycemic / counter-regulatory branch) or it does not (down-weights that branch).

• →Pre-specify snack composition (e.g., string cheese + small piece of fruit; or peanut butter + whole-grain cracker) and timing (30-60 min before bed).
• →Run for 2 weeks paired with the structured sleep diary (diagnostic rank 17).
• →Coordinate with pediatric endocrinology so that a critical-sample plan (diagnostic rank 18) is in place if an awakening occurs during a future inpatient admission or sleep study.

A consistent bedtime, dimmed evening light (low blue-light exposure 1-2 hours before bed), a cool dark quiet bedroom, and a consistent wake time stabilize circadian rhythm and reduce sleep fragmentation. Sleep-HPA bidirectionality (Balbo 2010) - sleep disruption causes HPA dysregulation and HPA dysregulation causes sleep disruption, so foundational sleep hygiene addresses one half of the loop independently of any biomedical intervention.

Sleep hygiene is established standard-of-care advice for pediatric sleep disturbance and for circadian phase disorders. Effect sizes vary, but the intervention is universally recommended as the substrate before any pharmacologic or biomedical intervention. Particularly important for children with neurodevelopmental disorders, where sleep-onset and night-waking issues are common.

• →Establish or confirm a consistent bedtime / wake time, dimmed evening light starting 1-2 hours before bed, no screens in the bedroom, and a cool dark quiet sleep environment.
• →Coordinate with sleep medicine if questions arise.
• →Run as the foundation for the pre-bedtime snack trial (rank 12), the melatonin trial (rank 14), and the actigraphy/sleep diary (diagnostic rank 17).

Low-dose melatonin (0.3-1 mg, physiologic) is a circadian phase-shifting agent and is widely used in pediatric neurodevelopmental populations both for sleep-onset latency and for circadian-phase consolidation. Higher doses (1-3 mg, supraphysiologic) may also have a soporific effect. In children with autism / DEE-spectrum disorders, melatonin has the strongest sleep evidence base of any over-the-counter or prescription pediatric sleep agent. Targets the circadian-phase component of the 1.5-year nocturnal arousal phenotype independently of any HPA intervention.

Pediatric melatonin has the strongest sleep evidence base in autism and neurodevelopmental disorders of any pediatric sleep agent. Dose-response and timing-response are individual; dosing too late in the evening can delay rather than advance phase. Long-term safety is generally reassuring at standard doses, with the main concern being product purity (over-the-counter products vary in actual content). Pharmacy-grade melatonin or compounded melatonin is preferred.

• →Coordinate with sleep medicine or pediatric neurology for dosing and timing guidance.
• →Establish baseline with sleep hygiene (rank 13) and actigraphy (diagnostic rank 17) first so a pre-melatonin baseline exists.
• →Consider pairing with the pre-bedtime snack trial (rank 12) as a separable second arm if the snack trial alone is insufficient.

Children with confirmed HPA-axis insufficiency (AM cortisol below pediatric AI threshold, blunted ACTH stimulation, or persistently low salivary cortisol curve) are at risk of adrenal crisis during physiologic stress (significant illness, surgery, severe injury, future high-dose steroid taper) without prophylactic hydrocortisone stress dosing. Levi has had one 3-day IV methylprednisolone pulse (March 2026) without explicit pre/post HPA characterization; if a future repeat pulse is considered, characterizing baseline HPA reserve and pre-emptively planning stress-dose policy reduces risk.

Stress-dose hydrocortisone for children with documented adrenal insufficiency is established standard of care in pediatric endocrinology. Not disease-modifying for DEE-SWAS, but a safety guardrail that prevents avoidable iatrogenic crisis. The "gated on diagnosis" framing means this is policy-conditional, not preemptive.

• →Complete diagnostic ranks 14-15 (AM cortisol + ACTH, 4-point salivary cortisol).
• →If abnormal, coordinate with pediatric endocrinology to establish a written stress-dose plan, family-facing dosing card, and emergency-department guidance.
• →Pre-emptively review with the treating team before any planned future steroid pulse, surgery under sedation, or anticipated illness.